MedTrace Logo

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

NCT05238012 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2024-05-21

No results posted yet for this study

Summary

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes

Conditions

  • Metabolism Disorder, Lipid
  • Metabolism Disorder, Glucose

Interventions

DRUG

Xuezhikang Capsule

Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.

DRUG

Atorvastatin Calcium Tablets

Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Heart Health Research Center

    lead OTHER

Principal Investigators

  • Changsheng Ma, MD · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2024-04-02
Completion
2024-04-02

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238012 on ClinicalTrials.gov